Ph.D. Biochemistry, University of Hull, UK.
B.Sc. Biological Sciences Class I Honours, University of East Anglia, UK.
Nuffield Department of Medicine, University of Oxford, UK. Initially Senior Molecular Biologist, appointed University Research Lecturer 1999, appointed Reader in Vaccinology 2004, appointed Jenner Investigator 2006, appointed Professor of Vaccinology 2010.
Research Scientist, Delta Biotechnology Ltd., Nottingham.
Research Scientist, Leicester Biocentre, Leicester University.
Novel influenza vaccines including a human challenge study demonstrating vaccine efficacy via T cell responses to conserved internal antigens of influenza
Viral-vectored vaccines that work by inducing strong and protective T and B cell responses
In January 2020 I initiated production of ChAdOx1 nCoV-19, and this vaccine is now approved for emergency use in 172 countries, with more than 350 million doses administered.
Over 200 publications, h index = 92, See Google Scholar
Sarah Gilbert receives Freedom of the City of London
In recognition of her outstanding contribution to public health and science in her role as the Oxford Project Leader spearheading the development on the Oxford–AstraZeneca COVID-19 vaccine, Professor Dame Sarah Gilbert has been awarded the Freedom of the City of London.
Two Christ Church Senior Associate Research Fellows elected Fellows of the Academy of Medical Sciences
The Academy of Medical Sciences has elected eleven University of Oxford biomedical and health scientists to its fellowship, among them are two Christ Church Senior Associate Research Fellows, Professor Sarah Gilbert and Professor Graham Ogg.